Gabrielle's Angel Foundation for Cancer Research
Gabrielle’s Angel Foundation Medical Research Awards provide support to junior investigators whose cutting-edge, creative scientific proposals have the greatest potential of broadening the foundation’s understanding of, and treatment for, blood cancers. The Foundation focuses on projects for cancer prevention, detection, and treatment that are most likely to be translated into clinical trials within a 3-5 year period.
The Medical Research Awards are specifically designed to provide support at the early exponential phase in the junior investigator’s independent lab career. The Foundation’s stated purpose is to encourage the exploration of new areas of research in the hematologic malignancies; the kind of bold scientific ideas that lack sufficient data and/or may not be eligible for funding from more traditional mechanisms. The total award shall not exceed $225,000 or $75,000 per year for three years contingent on the submission of approved annual progress reports. Overhead cost cannot exceed 10% (or $22,500) of the total grant award ($7,500 per year).
- Applicant must hold a junior faculty position at a 501(c)(3) teaching research institution and have an MD, a PhD, or an MD/PhD from an accredited institution.
- Applicant must hold the designation of assistant professor (associate professors are ineligible) and must have institutional support either as an independent junior faculty member or tenure track.
- Applicant must have held his/her current position no longer than five years.
- Applicant must clearly state that he/she has independent research projects as well as independent resources and must have preliminary results and/or publications from their independent laboratory.
Letters of Intent
Letters of Intent are due Friday, May 5, 2017 via email to firstname.lastname@example.org. Letters of Intent should include the PI’s NIH Biosketch, a proposed title for the research project, and a brief 1-2 page abstract of the proposed research project. The selected investigators will be notified and invited to submit a full application by Winship.
Letter of Intent Deadline: 5:00 PM on Friday, May 5, 2017
Announcement of Nominee Selection: Friday, May 26, 2017
Gabrielle’s Angel Foundation Due Date: 12:00 PM on Friday, August 18, 2017
Aflac Pilot Grant
The Aflac Cancer and Blood Disorders Center seeks to promote the development of new research initiatives that have the potential to lead to new methods for diagnosing, preventing, and treating cancer and blood disorders as well as new peer-reviewed funding. It is anticipated that 3 or more pilot grants of $50,000 per grant will be funded for a 1-year period. For applications that demonstrate a new collaborative research initiative (either within or external to the Aflac division) a budget of up to $100,000 will be considered. No indirect costs will be funded.
Faculty members of the Aflac Cancer and Blood Disorders Center, including adjunct faculty in Pediatric Hematology/Oncology/BMT, are eligible to be principal investigators.
Letter of Intent
Email your letter of intent (max 0.75 pages) in PDF format to Judy Caruso (Judy.Caruso@choa.org) by 5:00 PM on May 1, 2017. In the letter, indicate: (1) project title, (2) names and affiliations of all investigators and collaborators, (3) if the project is considered basic, translational, or clinical research, (4) if the project constitutes a new collaborative effort (internal or external to the Aflac division), (5) if the principal investigator is considered a mentored junior faculty member or is a senior faculty member, and (6) a concise summary of the project aims.
Letter of Intent Deadline: 5:00 PM on Monday, May 1, 2017
Full Application Deadline: Wednesday, May 31, 2017
NRG NCORP Cancer Prevention and Control Pilot Projects
NRG Oncology NCORP is soliciting pilot projects for applications focused on NRG NCORP Cancer Prevention and Control priorities that will provide data that will directly lead to future phase II-III Cancer Prevention and Control concepts. Priorities for funding are:
- Cancer prevention research aimed at identifying and evaluating interventions to reduce the risk and incidence of cancer; priority will be given to concepts in women's health, and other concepts are welcome
- Cancer control research aimed at reducing the incidence and co-morbidity of cancer and its treatment focused on the four symptomatic management themes: neurotoxicity, cardiotoxicity, lymphedema, and inflammation (including cancer-related fatigue)
- Survivorship and palliative care interventions aimed at reducing toxicity and symptom burden, and improving quality of life
- Cancer disparity research, in collaboration with NRG Oncology's Health Disparities Research Program, focused on efforts to increase the participation of minorities and underserved populations in Cancer Prevention and Control studies
Integral to these priorities is the establishment of biospecimen repositories for molecular studies. Funding can be requested for up to $18,000 and is contingent upon NRG Oncology’s receipt of the Notice of Award from the Division of Cancer Prevention. One to two projects may be funded. Projects are to be completed by December 31, 2018.
Applicant must be an NRG Oncology member.
Instructions for Applicants
Please submit a proposal (max 5 pages) to email@example.com by 5pm ET, Friday, May 5, 2017. The application must include:
- Description of project, including summary of specific aims
- How the project will help lead to a Phase II or Phase III NCORP concept
- Are NRG Oncology resources required? (i.e., biospecimen materials, statistical support, etc.)
- Investigators who will participate in project
- Timeline [not included in the 5-page limit]
- NIH biosketch of PI [not included in the 5-page limit]
- Detailed budget [not included in the 5-page limit]
Application Deadline: Friday, May 5, 2017 at 5:00 PM ET
Submit Applications To:
Erica Field, MPH, MHA, CCRP, firstname.lastname@example.org
Direct Scientific Questions to NRG NCORP Co-Chairs:
Deborah Watkins Bruner, RN, PhD, FAAN, email@example.com
Larry Wickerham, MD, firstname.lastname@example.org
Joan Walker, MD, Joanemail@example.com
BRCA 1, 2 Research Collaborative Grants
The V Foundation is seeking grant applications for high risk, high reward multi-disciplinary convergence research and innovative translational research. In this call for letters of intent, the V Foundation is interested in any cancer type that is associated with inherited BRCA mutations. Research in areas such as mechanisms of cancer causation, therapy resistance, prevention or gene- environment interactions would be within the scope.
Each institution may nominate one applicant for each of the following grant categories:
Convergence Team Award (3-year, $2,100,000 grant)
Team projects should leverage novel collaborations between biomedical scientists and other researchers that might be brought into the field to work together across disciplines to drive our understanding and treatment of BRCA 1,2 related cancers. Each team must include experts in multiple disciplines to create a research plan and drive BRCA 1/-2 cancer research into new and innovative areas. The research may be basic, translational, clinical, or epidemiological in nature. We encourage collaborations within and between research institutions. If the award is made to a collaborative team across multiple institutions, the grant will be made to the institution that nominated the lead PI and that lead institution will manage any sub-contracts with collaborating institutions.
Translational Award (3-year, $600,000 grant)
Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 5 years. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.
- Applicant must be nominated by their Cancer Center Director if the research institution is a cancer center. The V Foundation does not review unsolicited applications.
- Applicant must be employed at a U.S. non-profit research institution (e.g., 501c3, Section 170).
- By the due date of the application, applicants who will lead this research team must be scientists who hold a faculty position at their cancer research institution. Non- promotable, adjunct, affiliated, temporary, part-time or acting faculty positions are not eligible for Principal Investigator nomination to lead the Translational Research Team. Applicants must be either U.S. Citizens or have a legal permit to work in the U.S. (either temporary or permanent).
Letters of Intent
Letters of Intent (not to exceed 3 pages; minimum font size 11) are due May 19, 2017 in a single PDF to firstname.lastname@example.org. Please save the cover page (click here to download) as page zero of your 3-page letter of intent. Page 1-2: describe what your research is and the impact it will have. Page 3: describe the people, expertise and research environment for the project.
Winship Letter of Intent Deadline: 5:00 PM on Friday, May 19, 2017
Winship Announcement of Nominee Selection: Friday, June 2, 2017
V Foundation LOI Review and Selection: July 2017
Full Applications Due to V Foundation: September 2017
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
The Behavioral Research Program, Epidemiology and Genomics Research Program, and Healthcare Delivery Research Program of the National Cancer Institute’s Division of Cancer Control and Population Sciences have collaborated on the release of a program announcement to study the utilization, adherence, and delivery of oral anticancer agents. Specifically, this program announcement encourages research grant applications to:
- Assess and describe the current state of oral anticancer medication utilization, delivery, and adherence;
- Identify structural, systemic, and psychosocial barriers to adherence; and
- Develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.